Gainers

• PACS Group (NYSE:PACS) shares increased by 15.4% to $36.8 during Monday's after-market session. The company's market cap stands at $5.2 billion. As per the news, the Q1 earnings report came out today.
• BioVie (NASDAQ:BIVI) shares moved upwards by 7.4% to $1.45. The company's market cap stands at $11.0 million.
• GT Biopharma (NASDAQ:GTBP) shares increased by 7.29% to $0.37. The market value of their outstanding shares is at $13.3 million.
• AbCellera Biologics (NASDAQ:ABCL) shares increased by 7.04% to $5.62. The market value of their outstanding shares is at $1.5 billion. As per the press release, Q1 earnings came out today.
• P3 Health Partners (NASDAQ:PIII) stock increased by 6.4% to $4.02. The market value of their outstanding shares is at $11.6 million.
• Advanced Biomed (NASDAQ:ADVB) shares moved upwards by 5.78% to $5.3. The company's market cap stands at $10.1 million.

Losers

• WORK Medical Tech Gr (NASDAQ:WOK) shares decreased by 27.6% to $2.84 during Monday's after-market session.
• Ensysce Biosciences (NASDAQ:ENSC) stock fell 14.04% to $0.33. The market value of their outstanding shares is at $3.2 million.
• aTyr Pharma (NASDAQ:ATYR) shares decreased by 12.65% to $0.83. The market value of their outstanding shares is at $92.7 million.
• CEL-SCI (AMEX:CVM) stock fell 12.3% to $1.24. The market value of their outstanding shares is at $14.3 million.
• Harrow (NASDAQ:HROW) shares declined by 10.81% to $33.93. The company's market cap stands at $1.4 billion. As per the news, the Q1 earnings report came out today.
• Odysight ai (NASDAQ:ODYS) stock declined by 10.53% to $4.25. The market value of their outstanding shares is at $74.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.